Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data

BACKGROUND: Metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (Her2−) breast cancer remains a significant cause of cancer-related mortality. First-line treatment with endocrine therapy (ET) with a cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, James M, Handorf, Elizabeth A, Montero, Alberto J, Goldstein, Lori J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177121/
https://www.ncbi.nlm.nih.gov/pubmed/35552450
http://dx.doi.org/10.1093/oncolo/oyac075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177121/
https://www.ncbi.nlm.nih.gov/pubmed/35552450
http://dx.doi.org/10.1093/oncolo/oyac075

Ejemplares similares